Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Eisai announced today that results from the global Phase III clinical study "EMBRACE" will be published online in The Lancet.

3 Mar 2011

Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine

Vical Incorporated announced today the receipt of Scientific Advice from the European Medicines Agency (EMA) recommending practical efficacy endpoints for a Phase 3 trial of the company's TransVax™ therapeutic cytomegalovirus (CMV) vaccine.

3 Mar 2011

U-M scientists identify potential target to treat aggressive prostate cancer

Researchers at the University of Michigan Comprehensive Cancer Center have identified a potential target to treat an aggressive type of prostate cancer. The target, a gene called SPINK1, could be to prostate cancer what HER2 has become for breast cancer.

3 Mar 2011

IAVI, THSTI collaborate to establish HIV Vaccine Design Program in India

The Translational Health Sciences and Technology Institute, an autonomous institute of the Indian government's Department of Biotechnology, and the International AIDS Vaccine Initiative announced today an agreement to jointly establish, operate and fund an HIV Vaccine Design Program in India.

2 Mar 2011

Calypte Biomedical completes new Aware HIV-1/2 oral fluid rapid test internal studies

Calypte Biomedical Corporation, a developer, manufacturer and marketer of HIV diagnostic tests, today announced successful completion of internal studies of its new Aware HIV-1/2 oral fluid rapid test for the US and international markets.

2 Mar 2011

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin in combination with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma patients.

1 Mar 2011

EPO cancels PDL's '216B European Patent

PDL BioPharma, Inc. announced today that the Technical Board of Appeal of the European Patent Office has cancelled its hearing in which three appellants sought to have a 2007 decision upholding PDL's European Patent No. 0 451 216B overturned and the patent revoked.

1 Mar 2011

New research reveals how maternal antibodies block immune response to measles virus

New research that reveals how maternal antibodies block an immune response to the measles virus is a first step toward improving current childhood vaccination practices, scientists say.

1 Mar 2011

Cummings School granted U.S. Patent for antibody-based treatment against Hemolytic Uremic Syndrome

Researchers at the Cummings School of Veterinary Medicine have received U.S. patent approval for an antibody-based treatment for Hemolytic Uremic Syndrome (HUS), a potentially fatal outcome of E. coli poisoning and the leading cause of kidney failure in children.

1 Mar 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

Arsanis closes Series A financing for $10 million

Arsanis, Inc, a recently founded biotechnology company dedicated to the development of anti-infective monoclonal antibody therapeutics, today announced the closing of a Series A financing with a total funding amount of $10 million. Proceeds from the initial financing will be used to advance several programs in the anti-microbial infectious disease area.

28 Feb 2011

Pharming, Santarus receive FDA refusal to file letter for RHUCIN BLA

Specialty biopharmaceutical company Santarus, Inc.and biotech company Pharming Group NV today announced the receipt of a "refusal to file" letter from the U.S. Food and Drug Administration for the RHUCIN Biologics License Application submitted by Pharming.

28 Feb 2011

Study: HT may affect symptom load and quality of life unrelated to hypothyroidism

Hashimoto's thyroiditis, an inflammatory disorder of the thyroid, is the most common cause of hypothyroidism, but a study has suggested that even when thyroid function is normal, HT may increase symptoms and decrease quality of life, as described in an article in Thyroid, a peer-reviewed journal published by Mary Ann Liebert, Inc.

27 Feb 2011

Researchers capture complexities of breast cancer tumours to improve treatment, diagnostics

Breast cancer can develop very differently in different women. Researchers in Norway are improving breast cancer diagnostics and treatment by identifying the various tumour types. The objective is to find out as much as possible about the various tumour types so that each patient can receive precisely the right treatment at the right time.

25 Feb 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has granted a hearing to allow the company the opportunity to present its views on why Avastin® (bevacizumab) should remain FDA-approved for metastatic breast cancer (mBC). The FDA has scheduled the hearing for June 28 to 29, 2011.

25 Feb 2011

Transgenic fungal approach can fight against malaria and bug-borne diseases

New findings by a University of Maryland-led team of scientists indicate that a genetically engineered fungus carrying genes for a human anti-malarial antibody or a scorpion anti-malarial toxin could be a highly effective, specific and environmentally friendly tool for combating malaria, at a time when the effectiveness of current pesticides against malaria mosquitoes is declining.

24 Feb 2011

Antibody News and Research

Further Reading

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine

U-M scientists identify potential target to treat aggressive prostate cancer

IAVI, THSTI collaborate to establish HIV Vaccine Design Program in India

Calypte Biomedical completes new Aware HIV-1/2 oral fluid rapid test internal studies

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

EPO cancels PDL's '216B European Patent

New research reveals how maternal antibodies block immune response to measles virus

Cummings School granted U.S. Patent for antibody-based treatment against Hemolytic Uremic Syndrome

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Arsanis closes Series A financing for $10 million

Pharming, Santarus receive FDA refusal to file letter for RHUCIN BLA

Study: HT may affect symptom load and quality of life unrelated to hypothyroidism

Researchers capture complexities of breast cancer tumours to improve treatment, diagnostics

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Transgenic fungal approach can fight against malaria and bug-borne diseases

FDA approves sBLA for CSL's Hizentra to treat PI

Steroid administration may impact immune system in children with asthma

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Monoclonal Antibody Manufacturing Trends eBook eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News